Based on the insights provided by recent randomised phase 3 trials, while pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic NSCLC in patients with low PD-L1 expression (i.e., TPS ≥ 1%) [42], negative findings were achieved for nivolumab (an anti-PD-L1 drug) alone (CheckMate-026) or in combination (MYSTIC trial) [43]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.